Response rates (ORR, ITT, IRC-based), PFS, and OS in subgroups with adverse prognosis (N = 84)
| . | . | . | PFS (mo) . | OS (mo) . |
|---|---|---|---|---|
| Patients . | N . | ORR, N (%) . | Median (95%CI)/% at 1 y . | Median (95%CI)/% at 1 y . |
| ITT | 84 | 29 (34.5) | 4.6 (4, 7)/25.5 | 14.9 (11, 20)/57 |
| Refractory to lenalidomide | 75 | 27 (36) | 4.2 (3, 6)/23 | 13.9 (9, 18)/54.5 |
| Refractory to lenalidomide as last line * | 26 | 6 (23) | 4.4 (2, 9)/22 | 19.2 (9, —)/63 |
| Refractory to bortezomib | 68 | 20 (29) | 3.8 (3, 6)/24 | 13.8 (9, 18)/54 |
| Refractory to last line * | 71 | 23 (32) | 3.9 (3, 7)/25 | 13.9 (8.5, 19)/55 |
| Double refractory† | 64 | 20 (31) | 3.8 (3, 5)/24 | 13.8 (9, 16)/53 |
| More than 6 lines of therapy* | 19 | 4 (21) | 3.2 (2, 5)/16 | 9.2 (3, —)/47 |
| Del17p and/or t(4;14) | 21 | 6 (27) | 2.6 (2, 4)/5 | 5.4 (3, 9)/33 |
| . | . | . | PFS (mo) . | OS (mo) . |
|---|---|---|---|---|
| Patients . | N . | ORR, N (%) . | Median (95%CI)/% at 1 y . | Median (95%CI)/% at 1 y . |
| ITT | 84 | 29 (34.5) | 4.6 (4, 7)/25.5 | 14.9 (11, 20)/57 |
| Refractory to lenalidomide | 75 | 27 (36) | 4.2 (3, 6)/23 | 13.9 (9, 18)/54.5 |
| Refractory to lenalidomide as last line * | 26 | 6 (23) | 4.4 (2, 9)/22 | 19.2 (9, —)/63 |
| Refractory to bortezomib | 68 | 20 (29) | 3.8 (3, 6)/24 | 13.8 (9, 18)/54 |
| Refractory to last line * | 71 | 23 (32) | 3.9 (3, 7)/25 | 13.9 (8.5, 19)/55 |
| Double refractory† | 64 | 20 (31) | 3.8 (3, 5)/24 | 13.8 (9, 16)/53 |
| More than 6 lines of therapy* | 19 | 4 (21) | 3.2 (2, 5)/16 | 9.2 (3, —)/47 |
| Del17p and/or t(4;14) | 21 | 6 (27) | 2.6 (2, 4)/5 | 5.4 (3, 9)/33 |